Ongoing Selected Immunotherapy Trials in Bladder Cancer

Completed
Drug/AgentStudyStage of Disease
Atezolizumab (MPDL3280A) Anti-PD-L1Cohort 1 NCT02951767, Cohort 2: NCT02108652Phase IILocally advanced or metastatic – progressed after platinum-based treatment (Rosenberg et al. Lancet 2016; Balar et al. Lancet 2016 [63, 74])
PembrolizumabNCT02256436Phase III vs. standard of care chemotherapyLocally advanced or metastatic – progressed after platinum-based treatment
Ongoing
Drug/AgentStudyStage of Disease
Durvalumab with or without tremelimumabNCT02516241Phase II vs. standard of care chemotherapyStage IV transitional cell carcinoma of the urothelium
AtezolizumabNCT02662309Phase II preoperative MPDL3280ATransitional cell carcinoma of the bladder
Atezolizumab combination with cisplatin and gemcitabineNCT02989584Pilot safety, single-arm phase II studyMetastatic bladder cancer
AtezolizumabNCT02450331Randomized phase III atezolizumab as adjuvant therapy vs. observationPD-L1 positive, high risk muscle invasive bladder cancer
NivolumabNCT02632409Randomized phase III nivolumab as adjuvant therapy vs. placeboHigh risk muscle-invasive bladder cancer
Maintenance avelumabNCT02603432Phase III vs. best supportive care aloneLocally advanced or metastatic bladder cancer that did not progress after completion of first-line platinum containing chemotherapy
PembrolizumabNCT02335424Phase IINon-cisplatin eligible patients
MEDI-4736 (anti-PD-L1) +/− tremelimumab (anti-CTLA-4) NCT02516241Phase III, three arms: MEDI-4736 +/− tremelimumab vs. standard of care chemotherapyUnresectable stage IV bladder cancer